Targeting the endocannabinoid system in treating brain disorders

Expert Opinion on Investigational Drugs

Volumn 15, Issue 4, 2006, Pages 351-365

  Bahr, Ben A ^a,b   Karanian, David A ^a,b   Makanji, Sagar S ^a   Makriyannis, Alexandros ^b  

^a UNIVERSITY OF CONNECTICUT   (United States)

^b NORTHEASTERN UNIVERSITY   (United States)

Author keywords

2 arachidonoylglycerol; Anandamide; Anandamide transport; Cannabinoid receptor; Fatty acid amide hydrolase; Monoacylglycerol lipase; Neuroprotection

Indexed keywords

1 (2,4 DICHLOROPHENYL) 5 (4 IODOPHENYL) 4 METHYL N MORPHOLINO 1H PYRAZOLE 3 CARBOXAMIDE; 2 ARACHIDONOYLGLYCEROL; 2,3 DIHYDRO 5 METHYL 3 (MORPHOLINOMETHYL) 6 (1 NAPHTHOYL)PYRROLO[1,2,3 DE][1,4]BENZOXAZINE; 4 (1,1 DIMETHYLHEPTYL) 1',2',3',4',5',6' HEXAHYDRO 2,3' DIHYDROXY 6' (3 HYDROXYPROPYL)BIPHENYL; 6 IODO 3 (4 METHOXYBENZOYL) 2 METHYL 1 (2 MORPHOLINOETHYL)INDOLE; ACYLGLYCEROL LIPASE; ACYLGLYCEROL LIPASE INHIBITOR; AM 374; AMIDE; ANANDAMIDE; ANANDAMIDE TRANSPORT INHIBITOR; CANNABIDIOL; CANNABINOID; CANNABINOID RECEPTOR AGONIST; DEXANABINOL; DRONABINOL; ENDOCANNABINOID; ENZYME INHIBITOR; FATTY ACID; FATTY ACID AMIDASE; FATTY ACID AMIDASE INHIBITOR; FATTY ACID ESTER; LIGAND; METHANANDAMIDE; METHYLARACHIDONOYL FLUOROPHOSPHONATE; N (3 FURYLMETHYL)EICOSA 5,8,11,14 TETRAENAMIDE; N (4 HYDROXYPHENYL)ARACHIDONAMIDE; PALMITYLSULFONYLFLUORIDE; PHOSPHONIC ACID DERIVATIVE; RIMONABANT; UCM 707; UNCLASSIFIED DRUG; UNINDEXED DRUG;

BRAIN DISEASE; CELL REGENERATION; CENTRAL NERVOUS SYSTEM DISEASE; DEGENERATIVE DISEASE; DRUG INDICATION; DRUG TARGETING; HUMAN; NERVE CELL; NEUROPROTECTION; NONHUMAN; REVIEW; SIGNAL TRANSDUCTION;

ANIMALS; BRAIN DISEASES; DRUG DELIVERY SYSTEMS; ENDOCANNABINOIDS; HUMANS; RECEPTORS, CANNABINOID;

EID: 33645707847     PISSN: 13543784     EISSN: None     Source Type: Journal    
DOI: 10.1517/13543784.15.4.351     Document Type: Review

References (140)

1. GRUNDY RI: The therapeutic potential of the cannabinoids in neuroprotection. Expert Opin. Investig. Drugs (2002) 11:1365-1374.
2. DI MARZO V, MATIAS I: Endocannabinoid control of food intake and energy balance. Nat. Neurosci. (2005) 8:585-589.
3. MAKRIYANNIS A, MECHOULAM R, PIOMELLI D: Therapeutic opportunities through modulation of the endocannabinoid system. Neuropharmacology (2005) 48:1068-1071.
4. MATSUDA LA, LOLAIT SJ, BROWNSTEIN MJ, YOUNG AC, BONNER TI: Structure of a cannabinoid receptor and functional expression of cloned cDNA. Nature (1990) 346:561-564.
5. HERKENHAM M, LYNN AB, LITTLE MD et al.: Cannabinoid receptor localization in brain. Proc. Natl. Acad. Sci. USA (1990) 87:1932-1936.
6. 123I-labeled AM251: a radioiodinated ligand which binds in vivo to mouse brain cannabinoid CB1 receptors. Eur. J. Pharmacol. (1996) 307:331-338.
7. MARSICANO G, LUTZ B: Expression of the cannabinoid receptor CB1 in distinct neuronal subpopulations in the adult mouse forebrain. Eur. J. Neurosci. (1999) 12:4213-4225.
8. MATO S, DEL OLMO E, PAZOS A: Ontogenetic development of cannabinoid receptor expression and signal transduction functionality in the human brain. Eur. J. Neurosci. (2003) 17:1747-1754.
9. MOROZOV YM, FREUND TF: Post-natal development of Type 1 cannabinoid receptor immunoreactivity in the rat hippocampus. Eur. J. Neurosci. (2003) 18:1213-1222.
10. VAN DER STELT M, VELDHUIS WB, VAN HAAFTEN GW et al.: Exogenous anandamide protects rat brain against acute neuronal injury in vivo. J. Neurosci. (2001) 21:8765-8771.
11. MUNRO S, THOMAS KL, ABU-SHAAR M: Molecular characterization of a peripheral receptor for cannabinoids. Nature (1993) 365:61-65.
12. VAN SICKLE MD, DUNCAN M, KINGSLEY PJ et al.: Identification and functional characterization of brainstem cannabinoid CB2 receptors. Science (2005) 310:329-332.
13. BENITO C, NUNEZ E, TOLON RM et al.: Cannabinoid CB2 receptors and fatty acid amide hydrolase are selectively overexpressed in neuritic plaque-associated glia in Alzheimer's disease brains. J. Neurosci. (2003) 23:11136-11141.
14. BENITO C, KIM WK, CHAVARRIA I et al.: A glial endogenous cannabinoid system is upregulated in the brains of macaques with simian immunodeficiency virus-induced encephalitis. J. Neurosci. (2005) 25:2530-2536.
15. DEVANE WA, HANUS L, BREUER A et al.: Isolation and structure of a brain constituent that binds to the cannabinoid receptor. Science (1992) 258:1946-1949.
16. FELDER CC, JOYCE KE, BRILEY EM et al.: Comparison of the pharmacology and signal transduction of the human cannabinoid CB1 and CB2 receptors. Mol. Pharmacol. (1995) 48:443-450.
17. SHESKIN T, HANUS L, SLAGER J, VOGEL Z, MECHOULAM R: Structural requirements for binding of anandamide-type compounds to the brain cannabinoid receptor. J. Med. Chem. (1997) 40:659-667.
18. LIN S, KHANOLKAR AD, FAN P et al.: Novel analogues of arachidonylethanolamide (anandamide): affinities for the CB1 and CB2 cannabinoid receptors and metabolic stability. J. Med. Chem. (1998) 41:5353-5361.
19. UEDA N, OKAMOTO Y, TSUBOI K: Endocannabinoid-related enzymes as drug targets with special reference to N-acylphosphatidylethanolamine-hydrolyzing phospholipase D. Curr. Med. Chem. (2005) 12:1413-1422.
20. DI MARZO V, FONTANA A, CADAS H et al.: Formation and inactivation of endogenous cannabinoid anandamide in central neurons. Nature (1994) 372:686-691.
21. BELTRAMO M, STELLA N, CALIGNANO A, LIN SY, MAKRIYANNIS A, PIOMELLI D: Functional role of high-affinity anandamide transport, as revealed by selective inhibition. Science (1997) 277:1094-1097.
22. PIOMELLI D, BELTRAMO M, GLASNAPP S et al.: Structural determinants for recognition and translocation by the anandamide transporter. Proc. Natl. Acad. Sci. USA (1999) 96:5802-5807.
23. FEGLEY D, KATHURIA S, MERCIER R et al.: Anandamide transport is independent of fatty-acid amide hydrolase activity and is blocked by the hydrolysis-resistant inhibitor AM 1172. Proc. Natl. Acad. Sci. USA (2004) 101:8756-8761.
24. CRAVATT BF, GIANG DK, MAYFIELD SP, BOGER DL, LERNER RA, GILULA NB: Molecular characterization of an enzyme that degrades neuromodulatory fatty-acid amides. Nature (1996) 384:83-87.
25. CRAVATT BF, DEMAREST K, PATRICELLI MP et al.: Supersensitivity to anandamide and enhanced endogenous cannabinoid signaling in mice lacking fatty acid amide hydrolase. Proc. Natl. Acad. Sci. USA (2001) 98:9371-9376.
26. EGERTOVA M, CRAVATT BF, ELPHICK MR: Comparative analysis of fatty acid amide hydrolase and CB1 cannabinoid receptor expression in the mouse brain: evidence of a widespread role for fatty acid amide hydrolase in regulation of endocannabinoid signaling. Neuroscience (2003) 119:481-496.
27. MOROZOV YM, BEN-ARI Y, F REUND TF: The spatial and temporal pattern of fatty acid amide hydrolase expression in rat hippocampus during postnatal development. Eur. J. Neurosci. (2004) 20:459-466.
28. MECHOULAM R, BEN-SHABAT S, HANUS L et al.: Identification of an endogenous 2-monoglyceride, present in canine gut, that binds to cannabinoid receptors. Biochem. Pharmacol. (1995) 50:83-90.
29. SUGIURA T, KONDO S, SUKAGAWA A et al.: 2-Arachidonoylglycerol: a possible endogenous cannabinoid receptor ligand in brain. Biochem. Biophys. Res. Commun. (1995) 215:89-97.
30. STELLA N, SCHWEITZER P, PIOMELLI D: A second endogenous cannabinoid that modulates long-term potentiation. Nature (1997) 388:773-778.
31. BISOGNO T, SEPE N, MELCK D, MAURELLI S, DE PETROCELLIS L, DI MARZO V: Biosynthesis, release and degradation of the novel endogenous cannabimimetic metabolite 2-arachidonoylglycerol in mouse neuroblastoma cells. Biochem. J. (1997) 322:671-677.
32. DI MARZO V, BISOGNO T, DE PETROCELLIS L et al.: Biosynthesis and inactivation of the endocannabinoid 2-arachidonoylglycerol in circulating and tumoral macrophages. Eur. J. Biochem. (1999) 264:258-267.
33. DINH TP, CARPENTER D, LESLIE FM et al.: Brain monoglyceride lipase participating in endocannabinoid inactivation. Proc. Natl. Acad. Sci. USA (2002) 99:10819-10824.
34. DINH TP, KATHURIA S, PIOMELLI D: RNA interference suggests a primary role for monoacylglycerol lipase in the degradation of the endocannabinoid 2-arachidonoyloycerol. Mol. Pharmacol. (2004) 66:1260-1264.
35. BELTRAMO M, PIOMELLI D: Carrier-mediated transport and enzymatic hydrolysis of the endogenous cannabinoid 2-arachidonylglycerol. Neuroreport (2000) 11:1231-1235.
36. BISOGNO T, MacCARRONE M, DE PETROCELLIS L et al.: The uptake by cells of 2-arachidonoylglycerol, an endogenous agonist of cannabinoid receptors. Eur. J. Biochem. (2001) 268:1982-1989.
37. MARSICANO G, GOODENOUGH S, MONORY K et al.: CB1 cannabinoid receptors and on-demand defense against excitotoxicity. Science (2003) 302:84-88.
38. HANSEN HH, SCHMID PC, BITTIGAU P et al.: Anandamide, but not 2-arachidonoylglycerol, accumulates during in vivo neurodegeneration. J. Neurochem. (2001) 78:1415-1427.
39. MacCARRONE M, GUBELLINI P, BARI M et al.: Levodopa treatment reverses endocannabinoid system abnormalities in experimental parkinsonism. J. Neurochem. (2003) 85:1018-1025.
40. HOHMANN AG, SUPLITA RL, BOLTON NM et al.: An endocannabinoid mechanism for stress-induced analgesia. Nature (2005) 435:1108-1112.
41. GIUFFRIDA A, LEWEKE FM, GERTH CW et al: Cerebrospinal anandamide levels are elevated in acute schizophrenia and are inversely correlated with psychotic symptoms. Neuropsychopharmacology (2004) 29:2108-2114.
42. DI MARZO V, HILL MP, BISOGNO T, CROSSMAN AR, BROTCHIE JM: Enhanced levels of endogenous cannabinoids in the globus pallidus are associated with a reduction in movement in an animal model of Parkinson's disease. FASEB J. (2000) 14:1432-1438.
43. PANIKASHVILI D, SIMENIDOU C, BEN-SHABAT S et al.: An endogenous cannabinoid (2-arachidonylglycerol) is neuroprotective after brain injury. Nature (2001) 413:527-531.
44. BAKER D, PRYCE G, CROXFORD, JL et al.: Endocannabinoids control spasticity in a multiple sclerosis model. FASEB J. (2001) 12:300-302.
45. HOWLETT AC, QUALY JM, KHACHATRIAN LL: Involvement of Gi in the inhibition of adenylate cyclase by cannabimimetic drugs. Mol. Pharmacol. (1986) 29:307-313.
46. MACKIE K, LAI Y, WESTENBROEK R, MITCHELL R: Cannabinoids activate an inwardly rectifying potassium conductance and inhibit Q-type calcium currents in AtT20 cells transfected with rat brain cannabinoid receptor. J. Neurosci. (1995) 15:6552-6561.
47. DEADWYLER SA, HAMPSON RE, MU J, WHYTE A, CHILDERS S: Cannabinoids modulate voltage sensitive potassium A-current in hippocampal neurons via a cAMP-dependent process. J. Pharmacol. Exp. Ther. (1995) 2073:734-743.
48. GOMEZ DEL PULGAR T, VELASCO G, GUZMAN M: The CB1 cannabinoid receptor is coupled to the activation of protein kinase B/Akt. Biochem. J. (2000) 347:369-373.
49. MOLINA-HOLGADO F, PINTEAUX E, HEENAN L et al.: Neuroprotective effects of the synthetic cannabinoid HU-210 in primary cortical neurons are mediated by phosphatidylinositol 3-kinase/AKT signaling. Mol. Cell Neurosci. (2005) 28:189-194.
50. KARANIAN DA, BROWN QB, MAKRIYANNIS A, BAHR BA: Blocking cannabinoid activation of FAK and ERK1/2 compromises synaptic integrity in hippocampus. Eur. J. Pharmacol. (2005) 508:47-56.
51. MAEJIMA T, HASHIMOTO K, YOSHIDA T, AIBA A, KANO M: Presynaptic inhibition caused by retrograde signal from metabotropic glutamate to cannabinoid receptors. Neuron (2001) 31:463-475.
52. WILSON RI, NICOLL RA: Endogenous cannabinoids mediate retrograde signalling at hippocampal synapses. Nature (2001) 410:588-592.
53. BERNARD C, MILH M, MOROZOV YM, BEN-ARI Y, FREUND TF, GOZLAN H: Altering cannabinoid signaling during development disrupts neuronal activity. Proc. Natl. Acad. Sci. USA (2005) 102:9388-9393.
54. HENTGES ST, LOW MJ, WILLIAMS JT: Differential regulation of synaptic inputs by constitutively released endocannabinoids and exogenous cannabinoids. J. Neurosci. (2005) 25:9746-9751.
55. WALLACE MJ, MARTIN BR, DELORENZO RJ: Evidence for a physiological role of endocannabinoids in the modulation of seizure threshold and severity. Eur. J. Pharmacol. (2002) 452:295-301.
56. WALLACE MJ, BLAIR RE, FALENSKI KW, MARTIN BR, DELORENZO RJ: The endogenous cannabinoid system regulates seizure frequency and duration in a model of temporal lobe epilepsy. J. Pharmacol. Exp. Ther. (2003) 307:129-137.
57. KHASPEKOV LG, BRENZ VERCA MS, FRUMKINA LE et al.: Involvement of brain-derived neurotrophic factor in cannabinoid receptor-dependent protection against excitotoxicity. Eur. J. Neurosci. (2004) 19:1691-1698.
58. PARMENTIER-BATTEUR S, JIN K, MAO XO, KIE L, GREENBERG DA: Increased severity of stroke in CB1 cannabinoid receptor knock-out mice. J. Neurosci. (2002) 22:9771-9775.
59. PRYCE G, AHMED Z, HANKEY DJ et al.: Cannabinoids inhibit neurodegeneration in models of multiple sclerosis. Brain (2003) 126:2192-2202.
60. JACKSON SJ, PRYCE G, DIEMEL LT, CUZNER ML, BAKER D: Cannabinoid-receptor 1 null mice are susceptible to neurofilament damage and caspase 3 activation. Neuroscience (2005) 134:261-268.
61. PANIKASHVILI D, MECHOULAM R, BENI SM, ALEXANDROVICH A, SHOHAMI E: CB1 cannabinoid receptors are involved in neuroprotection via NF-KB inhibition. J. Cereb. Blood Flow Metab. (2005) 25:477-484.
62. BOUABOULA M, POINOT-CHAZEL C, BOURRIE B et al.: Activation of mitogen-activated protein kinases by stimulation of the central cannabinoid receptor CB1. Biochem. J. (1995) 312:637-641.
63. DERKINDEREN P, LEDENT C, PARMENTIER M, GIRAULT JA: Cannabinoids activate p38 mitogen-activated protein kinases through CB1 receptors in hippocampus. J. Neurochem. (2001) 77:957-960.
64. DERKINDEREN P, VALJENT E, TOUTANT M et al.: Regulation of extracellular signal-regulated kinase by cannabinoids in hippocampus. J. Neurosci. (2003) 23:2371-2382.
65. KOBAYASHI Y, ARAI S, WAKU K, SUGIURA T. Activation by 2-arachidonoylglycerol, an endogenous cannabinoid receptor ligand, of p42/44 mitogen-activated protein kinase in HL-60 cells. J. Biochem. (2001) 129:665-669.
66. GALVE-ROPERH I, RUEDA D, GOMEZ DEL PULGAR T, VELASCO G, GUZMAN M: Mechanism of extracellular signal-regulated kinase activation by the CB1 cannabinoid receptor. Mol. Pharmacol. (2002) 62:1385-1392.
67. KARANIAN DA, BROWN QB, MAKRIYANNIS A, KOSTEN TA, BAHR BA: Dual modulation of endocannabinoid transport and fatty acid amide hydrolase protects against excitotoxicity. J. Neurosci. (2005) 25:7813-7820.
68. BAHR BA, BENDISKE J, BROWN QB et al.: Survival signaling and selective neuroprotection through glutamatergic transmission. Exp. Neurol. (2002) 174:37-47.
69. DERKINDEREN P, TOUTANT M, BURGAYA F et al.: Regulation of a neuronal form of focal adhesion kinase by anandamide. Science (1996) 273:1719-1722.
70. DERKINDEREN P, TOUTANT M, KADARE G et al.: Dual role of Fyn in the regulation of FAK+6,7 by cannabinoids in hippocampus. J. Biol. Cbem. (2001) 276:38289-38296.
71. LIU J, BATKAI S, PACHER P et al.: Lipopolysaccharide induces anandamide synthesis in macrophages via CD14/MAPK/phosphoinositide 3-kinase /NF-κB independently of platelet-activating factor. J. Biol. Chem. (2003) 278:45034-45039.
72. BOMSER JA, QUISTAD GB, CASIDA JE: Chlorpyrifos oxon potentiates diacylglycerol-induced extracellular signal-regulated kinase (ERK 44/42) activation, possibly by diacylglycerol lipase inhibition. Toxicol. Appl. Pharmacol. (2002) 178:29-36.
73. 9-tetrahydrocannabinol are neuroprotective antioxidants. Proc. Natl. Acad. Sci. USA (1998) 95:8268-8273.
74. SHEN M, THAYER SA: Cannabinoid receptor agonists protect cultured rat hippocampal neurons from excitotoxicity. Mol. Pharmacol. (1998) 54:459-462.
75. 9-tetrahydrocannabinol on forebrain ischemia in rat. Brain Res. (2000) 857:183-187.
76. SINOR AD, IRVIN SM, GREENBERG DA: Endocannabinoids protect cerebral cortical neurons from in vitro ischemia in rats. Neurosci. Lett. (2000) 278:137-160.
77. HAYASE T, YAMAMOTO Y, YAMAMOTO K: Protective effects of cannabinoid receptor agonists against cocaine and other convulsant-induced toxic behavioural symptoms. J. Pharm. Pharmacol. (2001) 53:1525-1532.
78. 9-tetrahydrocannabinol against N-methyl-d-aspartate-induced AF5 cell death. Mol. Brain Res. (2005) 134:215-225.
79. LONG LE, MALONE DT, TAYLOR DA: Cannabidiol reverses MK-801-induced disruption of prepulse inhibition in mice. Neuropsychopharmacology (2006) (In Press).
80. MARSICANO G, MOOSMANN B, HERMANN H, LUTZ B, BEHL C: Neuroprotective properties of cannabinoids against oxidative stress: role of the cannabinoid receptor CB1. J. Neurochem. (2002) 80:448-456.
81. KIM SH, WON SJ, MAO XO, FIN K, GREENBERG DA: Involvement of protein kinase A in cannabinoid receptor-mediated protection from oxidative neuronal injury. J. Pharmacol. Exp. Ther. (2005) 313:88-94.
82. BISOGNO T, HANUS L, DE PETROCELLIS L et al.: Molecular targets for cannabidiol and its synthetic analogues: effect on vanilloid VR1 receptors and on the cellular uptake and enzymatic hydrolysis of anandamide. Br. J. Pharmacol. (2001) 134:845-852.
83. 1A receptor-dependent mechanism. Stroke (2005) 36:1077-1082.
84. MARTINEZ-ORGADO J, FERNANDEZ-FRUTOS B, GONZALES R et al.: Neuroprotection by the cannabinoid agonist WIN-55212 in an in vivo newborn rat model of acute severe asphyxia. Mol. Brain Res. (2003) 114:132-139.
85. 9-tetrahydrocannabinol and cannabidiol in N-methyl-D-aspartate-induced retinal neurotoxicity: involvement of peroxynitrite. Am. J. Pathol. (2003) 163:1997-2008.
86. MAULER F, MITTENDORF J, HORVATH E, DE VRY J: Characterization of the diarylether sulfonylester (-)-(R)-3-(2-hydroxymethylindanyl-4-oxy)-phenyl-4,4,4-trifluoro-1- sulfonate (BAY 38-7271) as a potent cannabinoid receptor agonist with neuroprotective properties. J. Pharmacol. Exp. Ther. (2002) 302:359-368.
87. MAULER F, HINZ V, AUGSTEIN KH, FASSBENDER M, HORVATH E: Neuroprotective and brain edema-reducing efficacy of the novel cannabinoid receptor agonist BAY 38-7271. Brain Res. (2003) 989:99-111.
88. LEKER RR, GAI N, MECHOULAM R, OVADIA H: Drug-induced hypothermia reduces ischemic damage: effects of the cannabinoid HU-210. Stroke (2003) 34:2000-2006.
89. SHOHAMI E, NOVIKOV M, MECHOULAM R: A nonpsychotropic cannabinoid, HU-211, has cerebroprotective effects after closed head injury in the rat. J. Neurotrauma (1993) 10:109-119.
90. BELAYEV L, BAR-JOSEPH A, ADAMCHIK J, BIEGON A: HU-211, a nonpsychotropic cannabinoid, improves neurological signs and reduces brain damage after severe forebrain ischemia in rats. Mol. Chem. Neuropathol. (1995) 25:19-33.
91. BAR-JOSEPH A, BERKOVITCH Y, ADAMCHIK J, BIEGON A: Neuroprotective activity of HU-211, a novel NMDA antagonist, in global ischemia in gerbils. Mol. Chem. Neuropathol. (1994) 23:125-135.
92. YOLES E, BELKIN M, SCHWARTZ M: HU-211, a nonpsychotropic cannabinoid, produces short- and long-term neuroprotection after optic nerve axotomy. J. Neurotrauma (1996) 13:49-57.
93. FILBERT MG, FORSTER JS, SMITH CD, BALLOUGH GP: Neuroprotective effects of HU-211 on brain damage resulting from soman-induced seizures. Ann. NY Acad. Sci. (1999) 890:505-514.
94. LEKER RR, SHOHAMI E, ABRAMSKY O, OVADIA H: Dexanabinol; a novel neuroprotective drug in experimental focal cerebral ischemia. J. Neurol. Sci. (1999) 162:114-119.
95. NAGAYAMA T, SINOR AD, SIMON RP et al.: Cannabinoids and neuroprotection in global and focal cerebral ischemia and in neuronal cultures. J. Neurosci. (1999) 19:2987-2995.
96. ZHUANG SY, BRIDGES D, GRIGORENKO E et al.: Cannabinoids produce neuroprotection by reducing intracellular calcium release from ryanodine-sensitive stores. Neuropharmacology (2005) 48:1086-1096.
97. RAMIREZ B, BLAZQUEZ C, GOMEZ DEL PULGAR T, GUZMAN M, DE CEBALLOS M: Prevention of Alzheimer's disease pathology by cannabinoids: neuroprotection mediated by blockade of microglia activation. J. Neurosci. (2005) 258:1904-1913.
98. IUVONE T, ESPOSITO G, ESPOSITO R, SANTAMARIA R, DI ROSA M, IZZO AA: Neuroprotective effect of cannabidiol, a non-psychoactive component from Cannabis sativa, on β-amyloid-induced toxicity in PC12 cells. J. Neurochem. (2004):89134-89141.
99. RAMAN C, McALLISTER SD, RIZVI G, PATEL SG, MOORE DH, ABOOD ME: Amyotrophic lateral sclerosis: delayed disease progression in mice by treatment with a cannabinoid. Amyotroph. Lateral Scler. Other Motor Neuron Disord. (2004) 5:33-39.
100. WEYDT P, HONG S, WITTING A et al.: Cannabinol delays symptom onset in SOD1 (G93A) transgenic mice without affecting survival. Amyotroph. Lateral Scler. Other Motor Neuron Disord. (2005) 6:182-184.
101. LASTRES-BECKER I, MOLINE-HOLGADO F, RAMOS JA, MECHOULAM R, FERNANDEZ-RUIZ J: Cannabinoids provide neuroprotection against 6-hydroxydopamine toxicity in vivo and in vitro: relevance to Parkinson's disease. Neurobiol. Dis. (2005) 19:96-107.
102. 9-tetrahydrocannabinol. J. Clin. Pharmacol. (1981) 21:413S-416S.
103. CLIFFORD DB: Tetrahydrocannabinol for tremor in multiple sclerosis. Ann. Neurol. (1983) 13:669-671.
104. 9-tetrahydrocannabinol: a novel treatment for experimental autoimmune encephalomyelitis. J. Neuroimmunol. (1989) 23:73-81.
105. WIRGUIN I, MECHOULAM R, BREUER A, SCHEZEN E, WEIDENFELD J, BRENNER T: Suppression of experimental autoimmune encephalomyelitis by cannabinoids. Immunopharmacology (1994) 28:209-214.
106. ACHIRON A, MIRON S, LAVIE V, MARGALIT R, BIEGON A: Dexanabinol (HU-211) effect on experimental autoimmune encephalomyelitis: implications for the treatment of acute relapses of multiple sclerosis. J. Neuroimmunol. (2000) 102:26-31.
107. BAKER D, PRYCE G, CROXFORD JL et al.: Cannabinoids control spasticity and tremor in a multiple sclerosis model. Nature (2000) 404:84-87.
108. ELMES SJ, WINYARD LA, MEDHURST SJ et al.: Activation of CB1 and CB2 receptors attenuates the induction and maintenance of inflammatory pain in the rat. Pain (2005) 118:327-335.
109. SAGAR DR, KELLY S, MILLNS PJ et al.: Inhibitory effects of CB1 and CB2 receptor agonists on responses of DRG neurons and dorsal horn neurons in neuropathic rats. Eur. J. Neurosci. (2005) 22:371-379.
110. MULLER-VAHL KR: Cannabinoids reduce symptoms of Tourette's syndrome. Expert Opin. Pharmacother. (2003) 4:1717-1725.
111. HANSEN HH, AZCOITIA I, PONS S et al.: Blockade of cannabinoid CB1 receptor function protects against in vivo disseminating brain damage following NMDA-induced excitotoxicity. J. Neurochem. (2002) 82:154-158.
112. GASPERI V, FEZZA F, SPAGNUOLO P, PASQUARIELLO N, MacCARRONE M: Further insights into the regulation of human FAAH by progesterone and leptin implications for endogenous levels of anandamide and apoptosis of immune and neuronal cells. Neurotoxicology (2005) 26:811-817.
113. 9-tetrahydrocannabinol. J. Neurosci. (1998) 18:5322-5332.
114. 9-tetrahydrocannabinol promote necrotic cell death but inhibit Fas-mediated apoptosis. Toxicol. Appl. Pharmacol. (2001) 174:264-272.
115. CLEMENT AB, HAWKINS EG, LICHTMAN AH, CRAVATT BF: Increased seizure susceptibility and proconvulsant activity of anandamide in mice lacking fatty acid amide hydrolase. J. Neurosci. (2003) 23:3916-3923.
116. 9-tetrahydrocannabinol increases C6 glioma cell death produced by oxidative stress. Neuroscience (2005) 134:567-574.
117. KATHURIA S, GAETANI S, FEGLEY D et al.: Modulation of anxiety through blockade of anandamide hydrolysis. Nat. Med. (2003) 9:76-81.
118. GIFFORD AN, BRUNEUS M, LIN S et al.: Potentiation of the action of anandamide on hippocampal slices by the fatty acid amide hydrolase inhibitor, palmitylsulphonyl fluoride (AM 374). Eur. J. Pharmacol. (1999) 383:9-14.
119. ARIZZI MN, CERVONE KM, ABERMAN JE et al.: Behavioral effects of inhibition of cannabinoid metabolism: the amidase inhibitor AM374 enhances the suppression of lever pressing produced by exogenously administered anandamide. Life Sci. (2004) 74:1001-1011.
120. KARANIAN DA, BUTLER D, MAKRIYANNIS A, BAHR BA: A reversible FAAH inhibitor exhibits efficient bioavailability while enhancing neuroprotective endocannabinoid responses. FASEB J. (2006) (In Press).
121. GIUFFRIDA A, RODRIQUEZ DE FONSECA FK, NAVA F, LOUBET-LESCOULIE P, PIOMELLI D: Elevated circulating levels of anandamide after administration of the transport inhibitor, AM404. Eur. J. Pharmacol. (2000) 408:161-168.
122. MESTRE L, CORREA F, AREVALO-MARTIN A et al.: Pharmacological modulation of the endocannabinoid system in a viral model of multiple sclerosis. J. Neurochem. (2005) 6:1327-1339.
123. HAJOS N, KATHURIA S, DINH T, PIOMELLI D, FREUND TF: Endocannabinoid transport tightly controls 2-arachidonoyl glycerol actions in the hippocampus: effects of low temperature and the transport inhibitor AM404. Eur. J. Neurosci. (2004) 19:2991-2996.
124. FERNANDEZ-ESPEJO E, CARABALLO I, RODRIQUEZ DE FONSECA F et al.: Experimental parkinsonism alters anandamide precursor synthesis, and functional deficits are improved by AM404: a modulator of endocannabinoid function. Neuropsychopharmacology (2004) 29:1134-1142.
125. DE LAGO E, FERNANDEZ-RUIZ J, ORTEGA-GUTIERREZ et al.: UCM707, an inhibitor of the anandamide uptake, behaves as a symptom control agent in models of Huntington's disease and multiple sclerosis, but fails to delay/arrest the progression of different motor-related disorders. Eur. Neuropsychopharmacol. (2006) 16:7-18.
126. LASTRES-BECKER I, DE MIGUEL R, DE PETROCELLIS L, MAKRIYANNIS A, DI MARZO V, FERNANDEZ-RUIZ J: Compounds acting at the endocannabinoid and/or endovanilloid systems reduce hyperkinesia in a rat model of Huntington's disease. J. Neurochem. (2003) 84:1097-1109.
127. 2 receptor responses by an anandamide transport inhibitor. J. Neurosci. (2000) 20:3401-3407.
128. LIGRESTI A, CASCIO MG, PRYCE G et al.: New potent and selective inhibitors of anandamide reuptake with antispastic activity in a mouse model of multiple sclerosis. Br. J. Pharmacol. (2006) 147:83-91.
129. MAKARA JK, MOR M, FEGLEY D et al.: Selective inhibition of 2-AG hydrolysis enhances endocannabinoid signaling in hippocampus. Nat. Neurosci. (2005) 8:1139-1141.
130. 9-tetrahydrocannabinol. Synapse (1998) 30:298-308.
131. PARIA BC, MA W, ANDRENYAK DM et al.: Effects of cannabinoids on preimplantation mouse embryo development and implantation are mediated by brain-type cannabinoid receptors. Biol. Reprod. (1998) 58:1490-1495.
132. 9-tetrahydrocannabinol treatment produces a time-dependent loss of cannabinoid receptors and cannabinoid receptor-activated G proteins in rat brain. J. Neurochem. (1999) 73:2447-2459.
133. HAMPSON RE, DEADWYLER SA: Cannabinoids reveal the necessity of hippocampal neural encoding for short-term memory in rats. J. Neurosci. (2000) 20:8932-8942.
134. KIM D, THAYER SA: Cannabinoids inhibit the formation of new synapses between hippocampal neurons in culture. J. Neurosci. (2001) 21:RC146.
135. ANTONELLI T, TANGANELLI S, TOMASINI MC et al.: Long-term effects on cortical glutamate release induced by prenatal exposure to the cannabinoid receptor agonist (R)-(+)-[2,3-dihydro-5-methyl-3-(4-morpholinyl-methyl)pynolo[1,2,3-de]- 1,4-benzoxazin-6-yl]-1-naphthalenylmethanone: an in vivo microdialysis study in the awake rat. Neuroscience (2004) 124:367-375.
136. FERGUSSON DM, HORWOOD LJ, NORTHSTONE K: Maternal use of cannabis and pregnancy outcome. Br. J. Obstet. Gynaecol. (2002) 109:21-27.
137. FRIED PA, WATKINSON B, GRAY R: Differential effects on cognitive functioning in 13- to 16-year-olds prenatally exposed to cigarettes and marihuana. Neurotoxicol. Teratol. (2003) 25:427-436.
138. ZAJICEK JP, SANDERS HP, WRIGHT DE et al.: Cannabinoids in multiple sclerosis (CAMS) study: safety and efficacy data for 12 months follow up. J. Neurosurg. Neurosurg. Psychiatry (2005) 76:1664-1669.
139. 9-tetrahydrocannabinol exposure. J. Neurosci. (2005) 25:11619-11627.
140. 9-tetrahydrocannabinol and anandamide analogs in mice. Eur. J. Pharmacol. (2005) 510(1-2):59-68.